Evorel Sequi

If you are looking for information on other Evorel products, please see below:

First of all, thank you for choosing Numan. If your prescription request for Evorel Sequi transdermal patches has been accepted, or if you considering whether this treatment may be suitable for you, we'd like to help you learn how to use it to its best effect, and give you some important information before you start taking it. You can also refer to this page throughout your treatment.

Evorel Sequi is a form of sequential combined hormone replacement therapy (HRT) delivered via transdermal patches. Each monthly pack contains two types of patches: four Evorel 50 patches (containing estradiol 50mcg/day only) and four Evorel Conti patches (containing estradiol 50mcg/day and norethisterone acetate 170mcg/day), containing hormones which are steadily released through the skin (transdermal route) into your bloodstream over several days.

Evorel Sequi is used for the relief of menopausal symptoms in perimenopausal and postmenopausal women who have a uterus. It is also licensed for the prevention of osteoporosis in postmenopausal women at high risk of fractures

Many women notice an improvement in their symptoms within a few weeks of starting treatment. However, it can sometimes take up to three months for your body to adjust and for you to feel the full benefits.

Treatment with Evorel Sequi is over a four-week cycle. One patch should be applied to a clean, dry, and non-irritated area of skin on your lower abdomen or trunk, below the waistline. Do not apply it to your breasts or near your waistline where tight clothing might rub it off:

When and how to change a patch: Each patch is worn continuously and replaced twice a week (every 3 to 4 days). To help you remember, it is best to change your patch on the same two days each week, for example, every Monday and Thursday.

Missed dose: If you forget to change a patch, you should change it as soon as possible and apply the next one at the normal time on your original change days. However, if it is almost time for the next patch, you should skip the missed one and go back to your regular schedule. Only one patch should be applied at a time. There is an increased likelihood of break-through bleeding and spotting when a patch is not replaced at the normal time. Always take this medicine exactly as instructed, and check with your healthcare provider if you are not sure.

Therapy usually begins with one standard dose patch. Treatment is usually started with the lowest effective dose and can be adjusted by your clinician after a few months depending on your response with the dose increased or decreased as necessary. The goal of HRT is always to use the lowest effective dose for the shortest duration necessary to manage your symptoms.

There are no special dosage requirements for elderly patients, though experience in treating women over 65 years is limited. This medicine is not for use in children.

Pregnancy: Evorel Sequi is not a contraceptive and is intended for use only in post-menopausal women. If it is less than 12 months since your last menstrual period or you are under 50 years old, you may still need to use additional contraception to prevent pregnancy. Speak to your healthcare provider for advice on this. If you become pregnant while taking it, you must stop treatment immediately and contact your healthcare provider.

Breastfeeding: Evorel Sequi is not indicated during breastfeeding.

The norethisterone (progestogen) component in the second half of the each monthly cycle of treatment with Evorel Sequi is to protect the womb lining, which will lead to a monthly withdrawal bleed.

The most common side effect is skin irritation, redness, or itching at the site where the patch is applied. Other common side effects include headache, breast pain, nausea, and irregular bleeding. As a transdermal form of HRT, Evorel Sequi bypasses the liver and carries a lower risk of blood clots (venous thromboembolism) compared to other systemic forms of HRT, such as oral tablets or capsules. The other risks associated with systemic HRT, such as a small increased risk of breast cancer and stroke, still apply, although the overall risk remains low for most patients being treated. For a full list of side effects, please see the Patient Information Leaflet provided with your medication and also linked at the bottom of this page.

Your clinician will review your treatment after three months to check how you’re responding. After that, you should have a check-up at least once a year. These reviews will assess whether HRT is still right for you, make sure your symptoms are under control, ask about any side effects and vaginal bleeding, request a check of your weight and your blood pressure, and decide if you need further tests such as a bone density scan. You should also examine your breasts regularly, and make sure to attend all routine screening appointments such as mammograms and cervical screening, if applicable to you. If you have a premature menopause, the risks of using HRT may be different, which you should discuss with your clinician.

You should stop using Evorel Sequi immediately and consult your doctor if you experience any of the following: signs of a blood clot (e.g. painful swelling in the leg), a swollen face, tongue and/or throat and/or difficulty swallowing or hives, together with difficulty breathing which are suggestive of an angioedema, jaundice (yellowing of the skin or eyes), a significant increase in your blood pressure, the new onset of a migraine-type headache, or if you become pregnant. When you and your clinician decide it is time to stop HRT, the dose is often reduced gradually to help prevent your menopausal symptoms from returning suddenly.

If you have any of following conditions are present, or if they have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, you should be closely supervised. It should be taken into account that these conditions may recur or be aggravated during treatment with Evorel Sequi Transdermal Patches, in particular:

Store at room temperature, at or below 25°C, within the original sachet and box. Keep out of reach of children, including used and disposed patches.

If you have questions about your medication, wish to discuss alternative treatment plans, or need reassurance, our clinicians are available to provide expert advice and support. Just email us at [email protected].

Lastly, please read the Patient Information Leaflet linked below and included with your treatment for a full list of side effects, contraindications, and precautions.